Jami Rubin - 06 Jun 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Reporting relationship: Director
Issuer ticker: RLAY
Reported as of: 06 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 17:50:40 UTC
Prior SEC filing: 20 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Brian Adams, as Attorney-in-Fact

Key filing fact

Jami Rubin filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 06 Jun 2025.

Key facts

This page summarizes Jami Rubin's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 17:50.

Change

Previous filing in this sequence was filed on 20 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816484 Primary reporting owner

Rubin Jami

Relationship: Director
Address: C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE
Signature: /s/ Brian Adams, as Attorney-in-Fact
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLAY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +136,681
Change %
Price: $0.000000
Shares after: 136,681
Date: 06 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 136,681
Exercise price: $3.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.